.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CD01_Paclitaxel.Paclitaxel .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CD01_Paclitaxel.Paclitaxel| name: | Paclitaxel |
| ATC code: | L01CD01 | route: | intravenous |
| n-compartments | 3 |
Paclitaxel is an antineoplastic agent that promotes microtubule assembly and stabilization, inhibiting cell division. It is commonly used to treat various cancers such as ovarian, breast, lung, and Kaposi's sarcoma. It is FDA approved and widely used in oncology today.
Pharmacokinetic parameters reported in adult cancer patients (both sexes), typically received paclitaxel as a 3-hour intravenous infusion as part of chemotherapy regimens.
He, J, et al., & Zhi, J (2022). Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. CPT: pharmacometrics & systems pharmacology 11(7) 867–879. DOI:10.1002/psp4.12799 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35470967
Ozols, RF, et al., & Baergen, R (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(17) 3194–3200. DOI:10.1200/JCO.2003.02.153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12860964
Bulitta, JB, et al., & Jusko, WJ (2009). Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer chemotherapy and pharmacology 63(6) 1049–1063. DOI:10.1007/s00280-008-0827-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18791718